严重中性粒细胞减少症：晚期/复发性结直肠癌患者口服曲氟尿苷-替匹嘧啶（TAS-102）化疗的一个预后指标
Severe neutropenia: a prognosticator in patients with advanced/recurrent colorectal cancer oral trifluridine-tipiracil (TAS-102) chemotherapy.
作者信息
Kimura M, Usami E, Iwai M, Teramachi H, Yoshimura T
出版信息
Pharmazie. 2017 Jan 10;72(1):49-52. doi: 10.1691/ph.2017.6808.
BACKGROUND/AIM: The effect of oral trifluridine-tipiracil (TAS-102)-induced neutropenia on survival of patients with advanced/recurrent colorectal cancer was investigated.
PATIENTS AND METHODS
Between August 2014 and May 2016, 41 patients underwent TAS-102 monotherapy at Ogaki Municipal Hospital. Risk factors for survival were examined by univariate and multivariate analyses.
RESULTS
In 41 patients, mild neutropenia (grade 1-2) occurred in 10 patients (24.4%), severe neutropenia (grade 3-4) occurred in 13 (31.7%), and 18 (43.9%) did not experience neutropenia. The median overall survival times in the absent, mild, and severe groups were 120 days (95% confidence interval [CI], 67-179), 184 days (95% CI, 94-274), and 299 days (95% CI, 192-404), respectively (p = 0.045). In patients with severe neutropenia, the death hazard ratio was 0.442 (95% CI, 0.201-0.974; p = 0.042).
CONCLUSION
In patients with advanced/recurrent colorectal cancer, TAS-102-induced severe neutropenia was associated with superior survival.
背景/目的：研究口服曲氟尿苷-替匹嘧啶（TAS-102）引起的中性粒细胞减少对晚期/复发性结直肠癌患者生存的影响。
患者与方法
2014年8月至2016年5月期间，41例患者在大垣市立医院接受TAS-102单药治疗。通过单因素和多因素分析检查生存的危险因素。
结果
41例患者中，10例（24.4%）出现轻度中性粒细胞减少（1-2级），13例（31.7%）出现重度中性粒细胞减少（3-4级），18例（43.9%）未出现中性粒细胞减少。无、轻度和重度组的中位总生存时间分别为120天（95%置信区间[CI]，67-179）、184天（95%CI，94-274）和299天（95%CI，192-404）（p = 0.045）。在重度中性粒细胞减少的患者中，死亡风险比为0.442（95%CI，0.201-0.974；p = 0.042）。
结论
在晚期/复发性结直肠癌患者中，TAS-102引起的重度中性粒细胞减少与较好的生存相关。
Zotero 插件